What was recalled
This page synthesizes the evidence and mechanism framework around Saccharomyces boulardii use in companion animals and commercial pet food. S. boulardii is a non-pathogenic yeast species that has been used as a probiotic in human medicine since the 1950s. The most-studied commercial strain is CNCM I-745 (Biocodex, France), with additional commercialized strains from various producers. Taxonomic studies have demonstrated that S. boulardii is genetically a strain or subspecies of Saccharomyces cerevisiae (bakers/brewers yeast), but clinical and regulatory frameworks treat it as a distinct entity due to substantial phenotypic differences: thermotolerance (grows optimally at 37°C versus 30°C for typical S. cerevisiae), inability to ferment galactose, distinct cell wall composition, and resistance to gastric acid passage. The strain is on EFSA QPS list and FDA GRAS inventory.
The human clinical evidence base for S. boulardii AAD prevention is among the strongest in probiotic literature. Multiple meta-analyses have synthesized 20+ randomized controlled trials (RCTs) of S. boulardii co-administered with antibiotic courses, documenting consistent reduction in AAD incidence (relative risk reduction of approximately 50% versus placebo). The Cochrane Collaboration meta-analysis (Goldenberg 2013, updated 2017) documented relative risk 0.47 (95% CI 0.35-0.63) for S. boulardii AAD prevention. Additional human evidence covers: (i) C. difficile-associated diarrhea recurrence prevention — McFarland 1994 documented reduced recurrence in patients with prior C. difficile infection; (ii) traveler's diarrhea prevention — Kollaritsch 1993 documented reduced incidence; (iii) chronic inflammatory bowel disease adjunctive support — Guslandi 2000 documented reduced relapse in Crohn's disease; (iv) acute gastroenteritis duration reduction — multiple pediatric trials documented reduced duration in children with viral gastroenteritis.
The companion-animal evidence base is substantially smaller but emerging. Published trials include: (i) D'Angelo 2018 J Vet Intern Med — dogs with acute diarrhea (n=25 probiotic arm, n=20 placebo), documented reduced clinical sign duration and fecal score improvement; (ii) Aktas 2007 Adv Clin Exp Med — dogs with acute diarrhea, documented improved fecal consistency; (iii) Hernandez 2012 — dogs with chronic enteropathy adjunctive use; (iv) limited feline data with smaller cohorts. The companion-animal trial dataset is approximately 5-10 published studies versus 20+ in humans, with most trials in dogs and limited feline-specific data. The trend is toward replicating the human AAD-prevention findings in companion animals, but the evidence base is not yet at the depth of the human evidence.
Why it was recalled
The structural concerns have three layers. Layer one — companion-animal evidence is emerging but not yet at human-evidence depth: the strong human AAD-prevention evidence (20+ RCTs, multiple meta-analyses) supports a clear clinical recommendation in human medicine. The companion-animal evidence is suggestive (5-10 trials documenting consistent direction of effect) but does not yet support the same depth of clinical recommendation. Veterinary clinical practice has begun adopting S. boulardii for canine AAD-prevention adjunctive use based on the cross-species evidence framework, but the practice is at an earlier evidence-maturation stage than the human practice.
Layer two — yeast-probiotic mechanism is distinct from bacterial probiotics and the framework requires educational attention: S. boulardii is fundamentally different from bacterial probiotics (Lactobacillus, Bifidobacterium, Enterococcus, Bacillus) in mechanism. The yeast is unaffected by antibacterial antibiotics, which makes co-administration during antibiotic courses uniquely effective (bacterial probiotic CFU drops substantially during antibiotic courses, while S. boulardii survives intact). The yeast produces specific anti-toxin enzymes (protease degrading C. difficile toxin A), secretes anti-inflammatory polyamines, and modulates intestinal epithelial cell function through receptor-binding mechanisms distinct from bacterial strain mechanisms. The framework difference rarely surfaces in consumer-facing pet food marketing, which typically lumps "probiotics" together regardless of bacterial-versus-yeast mechanism.
Layer three — commercial pet food inclusion at therapeutic dose is uncommon: human therapeutic S. boulardii dosing is typically 250 mg twice daily (approximately 5x10^9 CFU per dose). Veterinary clinical dosing in dogs is typically 250-500 mg twice daily for medium-large dogs and 125-250 mg twice daily for small dogs and cats. Commercial pet food inclusion of S. boulardii at therapeutic dose level requires substantially higher CFU loading than is typical for baseline probiotic-fortified kibble. The framework gap is that pet food formulations including S. boulardii at marketing-claim levels may not deliver therapeutic dose at typical daily feeding amounts, while veterinary-tier S. boulardii supplements at therapeutic dose typically outperform pet-food-included S. boulardii for specific clinical indications.
Health risks for your pet
S. boulardii safety profile is favorable across human and emerging companion-animal evidence. The strain carries EFSA QPS status and FDA GRAS status. Theoretical safety considerations: (i) fungemia in severely immunocompromised hosts — documented rare cases in human medicine include critically ill patients with central venous catheters, severe immunosuppression, or severe inflammatory bowel disease where the yeast translocates from gut lumen to bloodstream; case reports exist but absolute incidence is very low (estimated 1 in 5.6 million doses in adult ICU patients in one French surveillance study); (ii) contraindication in critically ill patients with central venous catheters per FDA labeling concerns (some hospitals avoid S. boulardii in ICU contexts due to fungemia risk); (iii) transient bloating, flatulence, or stool consistency change during initial supplementation (common; resolves 1-2 weeks); (iv) no interaction with antibacterial antibiotics (the yeast is intrinsically resistant to antibacterial antibiotics, which is the foundation of its AAD-prevention efficacy); (v) potential interaction with antifungal antibiotics (fluconazole, itraconazole, terbinafine reduce yeast viability and concurrent administration would be counterproductive).
The companion-animal safety record is favorable based on the limited published trial data and clinical use experience. Veterinary clinical practice generally considers S. boulardii safe for routine use in healthy and mildly-immunocompromised dogs and cats. Severely immunocompromised animals (chemotherapy, organ transplant, severe immunosuppression) warrant individualized veterinary consultation as with any live probiotic.
What to do if you bought affected product
Pet owners can use S. boulardii meaningfully through several practical approaches: (1) distinguish S. boulardii from bacterial probiotics — the yeast mechanism is fundamentally different and uniquely valuable during antibiotic courses; (2) consider S. boulardii for specific clinical contexts — acute diarrhea, antibiotic-associated diarrhea prevention during antibiotic courses, post-antibiotic recovery, traveler's GI distress (boarding kennel transitions), and adjunctive chronic enteropathy management carry the strongest evidence; (3) use veterinary-tier S. boulardii supplements for therapeutic indications — Florastor (Biocodex, human product widely used off-label in veterinary medicine), VetriMega Probiotic (containing S. boulardii alongside bacterial strains), and similar veterinary-targeted products typically deliver therapeutic dose more reliably than pet-food-included S. boulardii; (4) understand the dose framework — veterinary therapeutic dosing is 250-500 mg twice daily for medium-large dogs and 125-250 mg twice daily for small dogs and cats; commercial pet food inclusion at marketing-claim CFU levels may not deliver therapeutic dose at typical daily feeding; (5) use S. boulardii during antibiotic courses — the yeast is intrinsically resistant to antibacterial antibiotics, which makes co-administration uniquely effective for AAD prevention (bacterial probiotics drop in CFU substantially during antibiotic courses while S. boulardii survives intact); (6) continue S. boulardii 1-2 weeks post-antibiotic course — the post-antibiotic recovery window is when gut microbiota are vulnerable to opportunistic pathogen overgrowth (including C. difficile); continued S. boulardii supports recovery; (7) do not use S. boulardii concurrently with antifungal medications — fluconazole, itraconazole, and other antifungals reduce yeast viability; coordinate with your veterinarian if antifungal therapy is needed; (8) avoid S. boulardii in severely immunocompromised animals without veterinary consultation — chemotherapy, organ transplant, and severe immunosuppression contexts require individualized risk-benefit analysis due to rare fungemia risk.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate S. boulardii inclusion in pet food scoring per our published methodology. The yeast probiotic is uncommon in commercial pet food (more common in veterinary-tier supplements) and the evidence framework is at an earlier maturation stage than bacterial probiotics. Future rubric extension under consideration: brands publishing S. boulardii CNCM I-745 strain identification with CFU-at-end-of-shelf-life guarantee at therapeutic dose level would receive favorable scoring weight as evidence-quality signal. Related framework coverage is across our S. boulardii explainer, SF68 evidence, and probiotic strain viability controversy. For now, our recommendation: treat S. boulardii as a uniquely valuable yeast probiotic for antibiotic-associated diarrhea prevention and acute diarrhea adjunctive use, with awareness that veterinary-tier supplements typically deliver therapeutic dose more reliably than pet-food-included formulations.